Evogene | GenomeWeb

Evogene

NEW YORK (GenomeWeb) – Israel-based plant genetics firm Evogene today reported that its second quarter revenues declined 9 percent year over year, due to a sharp drop in revenues related to share purchases.

NEW YORK (GenomeWeb) – Evogene today said that its collaboration with Bayer CropScience for wheat improvement has been amended to focus on novel genomic promoters from a prior focus on the discovery of additional genes and SNPs.

NEW YORK (GenomeWeb) – Evogene and Marrone Bio Innovations today announced a collaboration to discover new modes of biological action for insect control and to develop and commercialize new insect control products.

NEW YORK (GenomeWeb News) – Evogene today announced the closing of its US initial public offering, raising $84.8 million in gross proceeds.

NEW YORK (GenomeWeb News) – Plant genomics firm Evogene has gone public in the US through the offering of 5 million shares of common stock at an offering price of $14.75 per share, bringing in gross proceeds of $73.75 million.

NEW YORK (GenomeWeb News) – Israeli plant genomics company Evogene said in an amended registration statement filed with the US Securities and Exchange Commission on Wednesday that it aims to raise $79 million in net proceeds through its initial public offering in the US.

NEW YORK (GenomeWeb News) – Evogene and Monsanto today announced they have expanded and extended an R&D collaboration aimed at identify plant genes related to yield, environmental stress, and fertilizer utilization.

NEW YORK (GenomeWeb News) – Israeli plant genomics firm Evogene today reported a 5 percent increase in revenues for its third quarter.

NEW YORK (GenomeWeb News) – Evogene today announced that it and DuPont Pioneer have extended and expanded their multiyear research collaboration aimed at developing varieties of soybean resistant to Asian Soybean Rust, or ASR.

NEW YORK (GenomeWeb News) – Plant genomics firm Evogene plans to go public in the US with an initial public offering of up to $60 million.

Pages

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.